WILMINGTON, DE / ACCESSWIRE / March 21, 2023 / Transparency Market Research Inc. - the aldosterone receptor antagonists market stood at USD 2.4 Bn in 2022 and it is expected to reach USD 4.5 Bn by 2031 with CAGR of 7.1%.

Rapid increase in usage of mineralocorticoid-receptor antagonists (MRA) to treat patients with heart failure and various forms of hypertension, such as resistant hypertension, is expected to augment the global aldosterone receptor antagonists market. Therapies based on aldosterone receptor antagonists are likely to become popular to treat cardiovascular diseases.

Request for a Sample PDF Report with Latest Industry Insights: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85448

Adoption of aldosterone receptor antagonist agents to improve renal function has increased significantly among patients suffering from chronic kidney diseases. These drugs work primarily by blocking epithelial and non-epithelial actions of aldosterone. These are effective in improving cardiovascular prognosis in patients after myocardial infarction. Rise in utilization of medications in tablet form is expected to augment the aldosterone receptor antagonists market outlook. Recent advances in third-generation MR antagonists are likely to bolster the market in the near future.

The healthcare industry is keen on reducing the cost of medications based on aldosterone receptor antagonists in order to make these affordable to people especially in low- and middle-income countries. Significant adoption of steroidal MRAs to treat and manage patients with heart failure is fueling the aldosterone receptor antagonists market industry. Increase in adoption is ascribed to availability of generic medicines based on steroidal MRAs.

Key Findings of Study

• Significant Adoption of Medications to Treat Heart Failure: Aldosterone receptor antagonists are gaining traction as a mono- or add-on therapy to treat heart failure. These improve survival rates among patients. High prevalence of cardiovascular diseases offers significant business opportunities for companies in the aldosterone receptor antagonists market.
• High Demand for Mineralocorticoid-Blocking Agents to Treat Hypertension: The TMR study on the aldosterone receptor antagonists market indicates that hypertension is a lucrative segment based on indications where the drugs are used. The hypertension segment accounted for major market share in 2022. High rate of utilization of aldosterone receptor antagonists to treat essential hypertension has propelled the segment in the past few years. Demand for these drugs has also increased significantly among patients with resistant hypertension. MRA therapy is a well-established add-on therapy in such patients.
• Rise in Preference for Mineralocorticoid Receptor Antagonist in Tablet Form: The study indicates that tablet form of aldosterone receptor antagonists is the most widely preferred among the patient population. The tablet segment held major share of the global market in 2022. The trend is anticipated to continue from 2023 to 2031. ARA with beta-blockers and ACE inhibitors are considered more effective than mono-therapy in the treatment of various indications, as these lower the risk of hospitalization and reduce mortality rate.

Have a Question? Speak to Research Expert: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85448

Key Drivers

• Rise in elderly population is driving the demand for drugs based on aldosterone receptor antagonists to treat heart failure and resistant hypertension. A few mineralocorticoid-blocking agents have been extensively utilized as a therapy to reduce blood pressure.
• High prevalence of hypertension and heart failure in populations globally is expected to bolster the aldosterone receptor antagonists market development
• Continuous advancements in drugs have led to availability of medications that effectively reduce the biological effects of aldosterone in the patient population and improve cardiovascular outcomes.

Regional Growth Dynamics

North America accounted for the leading market share in 2022. The trend is expected to continue from 2023 to 2031. High prevalence of hypertension and significant health burden of heart failure in the region, especially in the U.S., are the key factors likely to bolster market size. Companies are expected to increase market share by tapping into substantial demand for these drugs in the regional patient population.

Europe is anticipated to gain market share from 2023 to 2031. Surge in R&D activities in therapies that utilize mineralocorticoid-receptor antagonists to improve cardiovascular prognosis in the patient population is likely to bolster market growth. Launch of new products is likely to boost the market in the region.

Competition Landscape

The landscape is fragmented, with the presence of large number of players. Companies are focusing on new product development to increase market share and revenue. Prominent players operating in the market are RPG Life Sciences, Bayer HealthCare Pharmaceuticals LLC, CMP Pharma, AdvaCare Pharma, GEDEON, Sanofi, Intra Inventure, and AS Medication Solutions.

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=85448<>

Aldosterone Receptor Antagonists Market Segmentation

Drug Type

• Steroidal Mineralocorticoid Receptor Antagonists
• Non- steroidal Mineralocorticoid Receptor Antagonists

Dosage Form

• Tablets
• Suspensions
• Capsules
• Creams & Gels

Indication

• Hypertension
• Heart Failure
• Edema
• Primary Aldosteronism
• Others

Distribution Channel

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Stay Updated with Latest Pharmaceutical Industry Research Reports:

• Radiopharmaceutical Theranostics Market Growth, Analysis & Overview 2023-2031
• Peripheral Vasodilator Drugs Market Size, Share 2023-2031
• Antihyperlipidemic Drugs Market Share, Trends, Outlook 2022-2031
• Diuretic Drugs Market Size, Share, & Forecast, 2023-2033
• Penicillin G Acylase Market Size, Share, Trends, Overview, 2023-2031
• Anticoagulants Market Share, Analysis, Report 2023-2031
• Animal Drug Compounding Market Size Forecast, 2023-2031
• Alzheimer's Disease Biomarkers Market Share, Growth, Report 2023-2031
• Halal and Kosher Empty Capsules Market Size, Growth, Industry Trends 2023-2031
• Gemcitabine HCL Market Size, Share Industry Report 2023-2033

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

SOURCE: Transparency Market Research Inc.